STRATA Skin Sciences, Inc. (SSKN) Q3 2024 Earnings Call Transcript Summary
STRATA Skin Sciences, Inc. (SSKN) Q3 2024 Earnings Call Transcript Summary
Achieved first operating profit since 2018 when excluding a one-time accrual related to a sales tax audit.The following is a summary of the STRATA Skin Sciences, Inc. (SSKN) Q3 2024 Earnings Call Transcript:
以下是STRATA Skin Sciences, Inc.（SSKN）2024年第三季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
STRATA Skin Sciences reported a Q3 2024 revenue of $8.8 million, a decline of 1% year-over-year.
Gross margin increased to 60.3%, showing improvement for the third consecutive quarter.
Achieved first operating profit since 2018 when excluding a one-time accrual related to a sales tax audit.
Total operating expenses for Q3 2024 were $7 million, reduced by 7% year-over-year when adjusted for the one-time accrual.
STRATA Skin Sciences報告稱，2024年第三季度收入爲880萬美元，同比下降1％。
毛利率增至60.3％，連續第三個季度有所改善。
不包括與銷售稅審計有關的一次性應計費用，實現了自2018年以來的首次營業利潤。
2024年第三季度的總運營支出爲700萬美元，經一次性應計費用調整後同比減少7％。
Business Progress:
業務進展：
Revenue per XTRAC device grew by 2% year-over-year.
Strategic removal of underperforming XTRAC units aligns with efficiency goals.
Continued expansion and promising results in Direct to Consumer (DTC) initiatives, significantly increasing new patient appointments.
Deployment of TheraClearX devices increased along with securing insurance preauthorizations for acne treatments, enhancing treatment adoption.
每台 XTRAC 設備的收入同比增長了 2%。
從戰略上撤出表現不佳的 XTRAC 單位符合效率目標。
直接面向消費者（DTC）計劃的持續擴張和令人鼓舞的成果，顯著增加了新患者預約量。
TheraclearX設備的部署有所增加，同時獲得了痤瘡治療的保險預授權，從而提高了治療採用率。
Opportunities:
機會：
Expanding DTC initiatives, especially focusing on utilization of Spanish language efforts to broaden market reach.
Increasing the installed base and use of TheraClearX devices for acne treatment supported by positive study outcomes and professional endorsements.
擴大DTC計劃，特別側重於利用西班牙語努力擴大市場範圍。
在積極的研究結果和專業認可的支持下，增加用於痤瘡治療的TheraclearX設備的安裝量和使用量。
Risks:
風險：
Revenue declines in recurring billings underscore the challenge of reversing negative trends in this area.
Legal issues from sales tax audit and ongoing litigation indicate potential financial and reputational risks.
經常性賬單的收入下降凸顯了扭轉該領域負面趨勢的挑戰。
銷售稅審計和正在進行的訴訟中的法律問題表明了潛在的財務和聲譽風險。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
